TY - JOUR
T1 - Manganese-induced neurodegenerative diseases and possible therapeutic approaches
AU - Martins, Airton C.
AU - Gubert, Priscila
AU - Villas Boas, Gustavo R.
AU - Meirelles Paes, Marina
AU - Santamaría, Abel
AU - Lee, Eunsook
AU - Tinkov, Alexey A.
AU - Bowman, Aaron B.
AU - Aschner, Michael
N1 - Funding Information:
This work was supported by the National Institute of Environmental Health Sciences to MA [NIEHS R01ES007331 and R01ES10563] and EL [R01 ES024756].
Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/11
Y1 - 2020/11
N2 - Introduction: Neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis and prion disease represent important public health concerns. Exposure to high levels of heavy metals such as manganese (Mn) may contribute to their development. Areas covered: In this critical review, we address the role of Mn in the etiology of neurodegenerative diseases and discuss emerging treatments of Mn overload, such as chelation therapy. In addition, we discuss natural and synthetic compounds under development as prospective therapeutics. Moreover, bioinformatic approaches to identify new potential targets and therapeutic substances to reverse the neurodegenerative diseases are discussed. Expert opinion: Here, the authors highlight the importance of better understanding the molecular mechanisms of toxicity associated with neurodegenerative diseases, and the role of Mn in these diseases. Additional emphasis should be directed to the discovery of new agents to treat Mn-induced diseases, since present day chelator therapies have limited bioavailability. Furthermore, the authors encourage the scientific community to develop research using libraries of compounds to screen those compounds that show efficacy in regulating brain Mn levels. In addition, bioinformatics may provide novel insight for pathways and clinical treatments associated with Mn-induced neurodegeneration, leading to a new direction in Mn toxicological research.
AB - Introduction: Neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis and prion disease represent important public health concerns. Exposure to high levels of heavy metals such as manganese (Mn) may contribute to their development. Areas covered: In this critical review, we address the role of Mn in the etiology of neurodegenerative diseases and discuss emerging treatments of Mn overload, such as chelation therapy. In addition, we discuss natural and synthetic compounds under development as prospective therapeutics. Moreover, bioinformatic approaches to identify new potential targets and therapeutic substances to reverse the neurodegenerative diseases are discussed. Expert opinion: Here, the authors highlight the importance of better understanding the molecular mechanisms of toxicity associated with neurodegenerative diseases, and the role of Mn in these diseases. Additional emphasis should be directed to the discovery of new agents to treat Mn-induced diseases, since present day chelator therapies have limited bioavailability. Furthermore, the authors encourage the scientific community to develop research using libraries of compounds to screen those compounds that show efficacy in regulating brain Mn levels. In addition, bioinformatics may provide novel insight for pathways and clinical treatments associated with Mn-induced neurodegeneration, leading to a new direction in Mn toxicological research.
KW - Alzheimer’s disease
KW - Huntington’s disease
KW - Parkinson’s disease
KW - amyotrophic lateral sclerosis
KW - heavy metals
KW - manganese
UR - http://www.scopus.com/inward/record.url?scp=85090159979&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090159979&partnerID=8YFLogxK
U2 - 10.1080/14737175.2020.1807330
DO - 10.1080/14737175.2020.1807330
M3 - Review article
C2 - 32799578
AN - SCOPUS:85090159979
SN - 1473-7175
VL - 20
SP - 1109
EP - 1121
JO - Expert Review of Neurotherapeutics
JF - Expert Review of Neurotherapeutics
IS - 11
ER -